Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-18

Clinical Trial Update: Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

Phase 3 trial updating efficacy and safety of anifrolumab versus placebo in adults with active systemic lupus erythematosus. Results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Active Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2020-03-18